Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma

Eur J Surg Oncol. 2003 Oct;29(8):662-4. doi: 10.1016/s0748-7983(03)00147-1.

Abstract

Aim: We report the value of sentinel lymph node (SLN) biopsy and fluorodeoxyglucose-positron emission tomography (FDG-PET) in relation to SLN biopsy in staging primary cutaneous melanoma.

Methods: Fifty-five patients with primary cutaneous melanoma >1.0 mm. Breslow thickness and no palpable regional lymph nodes underwent a FDG-PET scan before SLN biopsy.

Results: SLN's were retrieved in 53 patients. Melanoma metastases were found in the SLN of 13 patients. FDG-PET detected the lymph node metastases in two of the 13 patients with SLN metastases. In five patients FDG accumulation was recorded in a regional lymph node basin, while no tumour positive SLN was found. In eight patients FDG-PET showed increased activity at a site of possible distant metastasis. Metastatic disease was confirmed in one patient. No explanation for the positive FDG-PET result could be found in five cases.

Conclusion: FDG-PET should not be considered in this group. SLN biopsy reveals regional metastases that are too small to be detected by FDG-PET. The prevalence of distant metastases is too small to justify routine use of FDG-PET.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphatic Metastasis
  • Male
  • Melanoma / diagnostic imaging*
  • Melanoma / surgery*
  • Middle Aged
  • Neoplasm Staging / methods
  • Predictive Value of Tests
  • Radiopharmaceuticals
  • Sentinel Lymph Node Biopsy*
  • Skin Neoplasms / diagnostic imaging*
  • Skin Neoplasms / surgery*
  • Tomography, Emission-Computed* / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18